Jenkem Technology Co., Ltd.

SHSE:688356 Stock Report

Market Cap: CN¥3.4b

Jenkem Technology Valuation

Is 688356 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688356 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688356 (CN¥56.01) is trading above our estimate of fair value (CN¥11.55)

Significantly Below Fair Value: 688356 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688356?

Key metric: As 688356 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 688356. This is calculated by dividing 688356's market cap by their current earnings.
What is 688356's PE Ratio?
PE Ratio70.7x
EarningsCN¥47.92m
Market CapCN¥3.39b

Price to Earnings Ratio vs Peers

How does 688356's PE Ratio compare to its peers?

The above table shows the PE ratio for 688356 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average33x
003020 Hefei Lifeon Pharmaceutical
21.2x24.6%CN¥3.7b
002082 Wanbangde Pharmaceutical Holding Group
36.4xn/aCN¥3.7b
000788 PKU HealthCareLtd
28.3xn/aCN¥3.6b
301201 ChengDa Pharmaceuticals
45.9xn/aCN¥3.2b
688356 Jenkem Technology
70.7x39.8%CN¥3.4b

Price-To-Earnings vs Peers: 688356 is expensive based on its Price-To-Earnings Ratio (70.7x) compared to the peer average (33x).

Price to Earnings Ratio vs Industry

How does 688356's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
688356 70.7xIndustry Avg. 29.6xNo. of Companies31PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 688356 is expensive based on its Price-To-Earnings Ratio (70.7x) compared to the CN Pharmaceuticals industry average (31.1x).

Price to Earnings Ratio vs Fair Ratio

What is 688356's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688356 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio70.7x
Fair PE Ratio32.1x

Price-To-Earnings vs Fair Ratio: 688356 is expensive based on its Price-To-Earnings Ratio (70.7x) compared to the estimated Fair Price-To-Earnings Ratio (32.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 688356 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥56.01
CN¥94.00
+67.8%
6.4%CN¥100.00CN¥88.00n/a2
Nov ’25CN¥54.69
CN¥94.00
+71.9%
6.4%CN¥100.00CN¥88.00n/a2
Oct ’25CN¥64.00
CN¥94.00
+46.9%
6.4%CN¥100.00CN¥88.00n/a2
Sep ’25CN¥51.80
CN¥94.00
+81.5%
6.4%CN¥100.00CN¥88.00n/a2
Aug ’25CN¥55.69
CN¥94.00
+68.8%
6.4%CN¥100.00CN¥88.00n/a2
Jul ’25CN¥61.35
CN¥94.00
+53.2%
6.4%CN¥100.00CN¥88.00n/a2
Jun ’25CN¥67.71
CN¥103.00
+52.1%
2.9%CN¥106.00CN¥100.00n/a2
Jan ’25CN¥106.40
CN¥145.50
+36.7%
17.5%CN¥170.99CN¥120.00n/a2
Dec ’24CN¥124.19
CN¥145.50
+17.2%
17.5%CN¥170.99CN¥120.00n/a2
Nov ’24CN¥126.07
CN¥145.50
+15.4%
17.5%CN¥170.99CN¥120.00CN¥54.692
Oct ’24CN¥122.00
CN¥145.50
+19.3%
17.5%CN¥170.99CN¥120.00CN¥64.002
Sep ’24CN¥92.84
CN¥175.50
+89.0%
2.6%CN¥180.00CN¥170.99CN¥51.802
Aug ’24CN¥106.90
CN¥175.50
+64.2%
2.6%CN¥180.00CN¥170.99CN¥55.692
Jul ’24CN¥106.55
CN¥175.50
+64.7%
2.6%CN¥180.00CN¥170.99CN¥61.352
Jun ’24CN¥112.64
CN¥175.50
+55.8%
2.6%CN¥180.00CN¥170.99CN¥67.712
May ’24CN¥125.83
CN¥175.50
+39.5%
2.6%CN¥180.00CN¥170.99CN¥80.052

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

7D

-4.2%

1Y

-23.6%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

7D

-3.0%

1Y

13.2%